PMID- 15270847
OWN - NLM
STAT- MEDLINE
DCOM- 20040920
LR  - 20181113
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 137
IP  - 2
DP  - 2004 Aug
TI  - Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in 
      the brains of herpes simplex virus type 1 infected BALB/c mice.
PG  - 305-12
AB  - Herpes simplex virus (HSV) is a common neurotropic virus which infects epithelial 
      cells and subsequently the trigeminal ganglia (TG) and brain tissue. We studied 
      how immunomodulation with roquinimex (Linomide) affects the course of corneal HSV 
      infection in BALB/c mice. BALB/c mice have also been used in a model for 
      HSV-based vectors in treating an autoimmune disease of the central nervous system 
      (CNS). We addressed the questions of how immunomodulation affects the local as 
      well as the systemic immune response and whether roquinimex could facilitate the 
      spread of HSV to the CNS. The cytokine response in the brain and TG was studied 
      using a quantitative rapid real-time RT-PCR method. We were interested in whether 
      immunomodulation affects the expression of the recently described Th1-cytokine 
      IL-23p19 in the brain and TG. The expression of IL-23 mRNA was decreased in 
      brains of roquinimex-treated BALB/c mice. Also the expression of IL-12p35 and 
      IFN-gamma mRNAs decreased. No significant changes were seen in IL-4 and IL-10 
      mRNA expression. The cytokine response was also studied using supernatants of 
      stimulated splenocytes by EIA. Roquinimex treatment suppressed the production of 
      IFN-gamma and also the production of IL-10 in HSV-infected BALB/c mice.
FAU - Peltoniemi, J
AU  - Peltoniemi J
AD  - Department of Virology, University of Turku, Turku, Finland. 
      jutta.peltoniemi@utu.fi
FAU - Broberg, E K
AU  - Broberg EK
FAU - Halenius, A
AU  - Halenius A
FAU - Setala, N
AU  - Setala N
FAU - Eralinna, J-P
AU  - Eralinna JP
FAU - Salmi, A A
AU  - Salmi AA
FAU - Roytta, M
AU  - Roytta M
FAU - Hukkanen, V
AU  - Hukkanen V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cytokines)
RN  - 0 (Hydroxyquinolines)
RN  - 0 (IL23A protein, human)
RN  - 0 (Il23a protein, mouse)
RN  - 0 (Interleukin-23)
RN  - 0 (Interleukin-23 Subunit p19)
RN  - 0 (Interleukins)
RN  - 0 (RNA, Messenger)
RN  - 130068-27-8 (Interleukin-10)
RN  - 372T2944C0 (roquinimex)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Brain/*immunology
MH  - Cytokines/biosynthesis/genetics
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - *Herpesvirus 1, Human
MH  - Hydroxyquinolines/*pharmacology
MH  - Interferon-gamma/biosynthesis/genetics
MH  - Interleukin-10/biosynthesis/genetics
MH  - Interleukin-23
MH  - Interleukin-23 Subunit p19
MH  - Interleukins/*biosynthesis/genetics
MH  - Keratitis, Herpetic/*immunology
MH  - Mice
MH  - RNA, Messenger/genetics
PMC - PMC1809122
EDAT- 2004/07/24 05:00
MHDA- 2004/09/21 05:00
PMCR- 2005/08/01
CRDT- 2004/07/24 05:00
PHST- 2004/07/24 05:00 [pubmed]
PHST- 2004/09/21 05:00 [medline]
PHST- 2004/07/24 05:00 [entrez]
PHST- 2005/08/01 00:00 [pmc-release]
AID - CEI2528 [pii]
AID - 10.1111/j.1365-2249.2004.02528.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2004 Aug;137(2):305-12. doi: 10.1111/j.1365-2249.2004.02528.x.